Repligen Corporation (RGEN) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.

Total Assets Chart for Repligen Corporation

Repligen Corporation (RGEN) total assets for FY2025 were USD 2.9B, a 4.2% change from FY2024. Repligen Corporation's total assets grew from USD 10.3M in 1985 to USD 2.9B in 2025 (28537.9% over 40 years). Total assets compound annual growth rate: 5-year CAGR of 9.2%, 10-year CAGR of 35.0%, 20-year CAGR of 26.1%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$9.87B
Implied Share Price
$174.86
Enterprise Value
$10.29B
Revenue (TTM)
$785.10M
EBITDA
$144.10M
Profit Margin
5.29%
Trailing P/E
260.99
Forward P/E
67.11
Price/Book (MRQ)
4.93
Price/Sales (TTM)
12.57
EV/EBITDA
53.61
EV/Revenue
11.72
Dividend Yield
—
Book Value
$37.43
Free Cash Flow (FY2025)
$93.90M
Free Cash Flow Yield
0.95%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.